Aura Biosciences Expands Executive Leadership Team with the Appointment of Mark De Rosch, Ph.D., as Chief Operating Officer
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Aura Biosciences, Inc., a clinical-stage oncology company developing a novel class of virus-like drug conjugate (VDC) therapies for multiple oncology indications, today announced the appointment of Mark De Rosch, Ph.D. as Chief Operating Officer. In his role, he will be responsible for leading Aura’s global operations and regulatory strategy.
Dr. De Rosch brings to Aura more than 30 years of experience in leading global regulatory and development strategies across many therapeutic areas, including oncology and ophthalmology. He has expertise in transitioning companies from early-stage to late-stage and in building effective teams to achieve clinical and corporate objectives.
“Mark joins our team during an exciting time at Aura. His decades of experience with global regulatory strategy, as well as building successful teams and pipelines, will be invaluable as we work to realize the full potential of our VDC technology platform,” said Elisabet de los Pinos, Ph.D., founder and CEO of Aura. “His proven track record and strong scientific acumen aligns well with our goals as we advance AU-011 toward late-stage pivotal development.”
“I am delighted to join Aura at this important time in the Company’s history and I look forward to being part of its promising future, as we work to become a leader in ocular oncology,” said Dr. De Rosch. “Aura’s experienced team and the novel VDC technology make this a compelling opportunity. I look forward to contributing my global regulatory, operational and organizational expertise to grow the Company and advance this leading technology to transform the outcomes for cancer patients.”
Dr. De Rosch joins Aura from Epizyme, where he served as Chief Regulatory Officer and led regulatory efforts for their first approved product, TAZVERIK® (tazemetostat). Prior to Epizyme, Dr. De Rosch served as Senior Vice President, Regulatory Affairs and Quality Assurance for Nightstar Therapeutics (acquired by Biogen in 2019), where he developed and implemented global regulatory roadmaps for their gene therapy programs in choroideremia and retinitis pigmentosa. Prior to Nightstar, he served as Senior Vice President, Regulatory Affairs, Quality Assurance and CMC at Akebia Therapeutics. Before that, Dr. De Rosch served in roles of increasing responsibility at several life science and healthcare consulting firms. Dr. De Rosch holds a Ph.D. and an M.S. in inorganic chemistry from the University of California, San Diego and a B.S. in chemistry/biochemistry from the University of Wisconsin-Parkside.
About Aura Biosciences
Aura Biosciences, Inc. is a clinical-stage oncology company developing a novel technology platform based on virus-like drug conjugates (VDCs) to target and destroy cancer cells selectively while activating the immune system to create long lasting anti-tumor immunity. The VDC technology platform is based on the pioneering discoveries of NIH distinguished investigator Dr. John Schiller of the Center for Cancer Research at the National Cancer Institute (NCI), recipient of the 2017 Lasker-DeBakey Award. The company has the goal of developing this technology in multiple cancer indications with an initial focus in ocular oncology, a group of rare diseases that have no drugs approved. Aura’s lead product candidate belzupacap sarotalocan (AU-011) is currently in Phase 2 development for the first line treatment of choroidal melanoma, a vision and life-threatening form of eye cancer where standard of care radioactive treatments leave patients with major vision loss and severe comorbidities. In a Phase 1b/2 study, AU-011 demonstrated compelling efficacy, including high rates of tumor control and vision preservation including patients with tumors close to the fovea and optic disk, along with a favorable safety profile. Future pipeline applications for Aura’s technology include additional ocular oncology indications like choroidal metastases and solid tumor indications like non-muscle invasive bladder cancer. Aura is headquartered in Cambridge, MA. For more information, visit www.aurabiosciences.com or follow us on Twitter.
Investor and Media:
617.340.6075 | email@example.com
Source: Aura Biosciences, Inc.